Literature DB >> 1895506

Prognostic significance of long ventricular pauses in athletes.

S Ogawa1, H Tabata, S Ohishi, H Hitomi, H Shiomi, H Akita, H Haga, M Katsurada.   

Abstract

The long-term prognosis of athletes with long ventricular pauses has been unknown. In this study, thirty highly-trained cross-country skiers and 24 age-matched controls underwent 24 h Holter monitoring to detect the duration of the longest ventricular pause (LVP), and we followed the athletes for more than 3 years to evaluate prognostic significance of prolonged LVP. The LVPs of the athletes averaged 2.2 +/- 0.6 sec (range 1.3-3.4), which were significantly longer than those, 1.6 +/- 0.3 sec, of the controls. In the athletes, 20 cases (66.7%) had LVPs more than 2 sec, and 5 (16.7%) showed LVPs longer than 3 sec. During 3 years follow-up, no athletes had symptoms of near syncope, syncope or death under continued heavy training. Our study suggested that athlete with prolonged ventricular pause, even of 3 sec or more, did not have a different clinical risk than those without long pauses.

Entities:  

Mesh:

Year:  1991        PMID: 1895506     DOI: 10.1253/jcj.55.761

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  3 in total

Review 1.  Outcomes among athletes with arrhythmias and electrocardiographic abnormalities: implications for ECG interpretation.

Authors:  David McClaskey; Daniel Lee; Eric Buch
Journal:  Sports Med       Date:  2013-10       Impact factor: 11.136

2.  Postural tachycardia syndrome with asystole on head-up tilt.

Authors:  Amer Alshekhlee; Meziane Guerch; Faisal Ridha; Kevin Mcneeley; Thomas C Chelimsky
Journal:  Clin Auton Res       Date:  2007-10-19       Impact factor: 4.435

Review 3.  Cardiac pauses in competitive athletes: a systematic review examining the basis of current practice recommendations.

Authors:  Tunay Senturk; Hai Xu; Krishna Puppala; Balaji Krishnan; Scott Sakaguchi; Lin Y Chen; Rehan Karim; Oana Dickinson; David G Benditt
Journal:  Europace       Date:  2015-11-20       Impact factor: 5.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.